Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene
Merger appetites and competitive dynamics will continue to be assessed as investors grill the next round of biopharma companies presenting first quarter sales and earnings. Gilead and Pfizer will be particularly pressed on deals.
You may also be interested in...
Strong Q1 results and a plan to refile ozanimod in early 2019 may help investors regain confidence in Celgene, but a lot depends on the company's pipeline, which had an additional setback with discontinuation of all GED-0301 development.
Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.
P&G’s planned acquisition of Merck KGaA’s consumer health care business will grow its consumer health portfolio 50%, expand its OTC drug and supplement business abroad and open up new categories. CEO David Taylor frames the acquisition as another step in the firm's ongoing portfolio shakeup.